首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到18条相似文献,搜索用时 406 毫秒
1.
脉冲电磁场合用钙剂治疗绝经后骨质疏松症的疗效观察   总被引:4,自引:2,他引:2  
目的 对脉冲电磁场 (PEMFs)治疗绝经后骨质疏松症疗效进行观察和探讨。方法 确诊为绝经后骨质疏松症 2 0例 ,采用磁振热机器 (选用其主要的脉冲电磁场成分 )加口服钙剂治疗 ,每次 1h ,共 30次 ,治疗 5 0d及治疗后 6个月观察其自觉症状改善情况及骨密度 (BMD)的变化 ,并与治疗前对比分析。结果 10 0 %患者疼痛明显减轻 ,治疗 5 0d结束时平均BMD绝对增长 0 0 4 8g/cm2 ,治疗后 6个月达 0 0 83g/cm2 。结论 PEMFs治疗绝经后骨质疏松症可以有效控制疼痛 ,提高患者的生存质量 ,对患者BMD也有一定程度的提高  相似文献   

2.
目的对脉冲电磁场(PEMFs)治疗老年性骨质疏松症的疗效进行观察和探讨。方法对相关病人进行问卷调查、骨密度及有关生化项目检测而诊断为老年性骨质疏松症的17例患者进行PEMFs治疗,观察治疗前、后自觉症状的改善情况及骨密度的变化,并与治疗前对比分析。结果(1)100%患者疼痛明显减轻。(2)64.71%患者骨密度提高5.6%以上(P<0.05)。结论PEMFs治疗老年性骨质疏松症可有效减轻自觉症状,对患者骨密度有一定程度的提高。  相似文献   

3.
社区护理干预对老年骨质疏松症患者的影响   总被引:5,自引:3,他引:2  
鄢凤仙 《护理学报》2006,13(5):64-65
目的观察社区护理干预对老年骨质疏松症患者的作用。方法按Doll设计的随机分配卡法将荔新福社区60例骨质疏松症患者随机分成两组,各30例,两组患者均在医生的指导下应用钙剂和降钙素。在饮食、运动、药物和心理方面进行护理干预为干预组,在医生的指导下进行药物治疗和常规护理为常规护理组;6个月后分析两组患者骨密度(BMD)及疼痛程度。结果干预组骨密度提高,疼痛减轻,与常规组比较均有显著性差异(P<0.05)。结论护理干预提高骨质疏松症患者的骨密度和减轻疼痛。  相似文献   

4.
低频脉冲电磁场对骨质疏松症的治疗作用   总被引:8,自引:1,他引:7  
目的进一步了解低频脉冲电磁场 ( PEMFS) 对骨质疏松 ( OP) 患者的作用 . 方法 72例原发性骨质疏松患者分成 3组 ( A组、 B组、 C组 ) , A组每天仅服用 1- γ羟基活性维生素 D 0.5 mg/d及元素钙 1 200 mg/d ; B组在服用上述药物的同时采用 HEMI骨质疏松治疗仪应用 PEMFS治疗 , C组除采用 B组治疗方案外 , 另增加 HESI骨骼肌内生高频诱发仪进行治疗 , 3组均进行了 30 d治疗 . 采用骨密度 ( BMD) 及超声声速 ( SOS) 进行评定 . 结果 3组治疗后 BMD均有所增长 , SOS除 A组外 B组、 C组均有好的明显变化 , 停止治疗 3个月后 , A组 BMD及 SOS明显下降 , B组较 A组的幅度降的要小 , C组不降反而有所上升 . 结论 PEMFS结合药物治疗比单纯用药更有效提高骨质疏松患者 BMD和 SOS. PEMFS配合骨骼肌内生高频诱发仪治疗 , 能取得更好的疗效 . 结论 PEMFS是临床治疗骨质疏松的一种有效手段 , 若有选择性结合其他治疗方法 , 会取得更好的临床效果 .  相似文献   

5.
目的:探讨鲑鱼降钙素联合护理干预对老年骨质疏松症患者骨痛及骨密度(BMD)的影响.方法:将120例老年骨质疏松症患者随机分为观察组和对照组各60例,对照组给予钙剂及维生素D药物治疗,观察组在此基础上加用鲑鱼降钙素及护理干预.比较两组干预前骨痛程度及BMD、治疗1个月后骨痛程度及治疗6个月后BMD变化.结果:治疗1个月后观察组骨痛程度改善明显优于对照组(P<0.05),治疗6个月后观察组骨密度较对照组明显提高(P<0.05).结论:鲑鱼降钙素联合护理干预能明显提高老年骨质疏松症患者的BMD,明显改善骨痛症状.  相似文献   

6.
目的对脉冲电磁场(PEMFs)治疗骨质疏松症的疗效进行观察和探讨.方法对67例原发性骨质疏松症患者进行PEMFs治疗,观察治疗前、后自觉症状的改善情况及骨密度的变化.结果全部患者疼痛明显减轻,70.15%患者骨密度提高5.6%以上(P  相似文献   

7.
目的:观察低频脉冲电磁场(pulsedelectromagneticfields,PEMFs)对原发性骨质疏松症的治疗作用。方法:对18例原发性骨质疏松症患者进行PEMFs治疗,40min/次,1次/d,每周治疗5次,共6周为1个疗程,观察其治疗作用。结果:治疗后在16例有疼痛症状的患者中,疼痛消失或缓解11例(P<0.05),总有效率为69%。血清骨钙素水平提高16.83%(P<0.05)。血总碱性磷酸酶水平无明显变化(P>0.05)。两个月后复查骨密度显示平均股骨颈骨密度提高4.34%(P<0.05),平均髋部Wards三角区骨密度提高10.19%(P<0.05),平均腰椎(L2~4)骨密度无明显提高(P>0.05)。治疗过程中及治疗后无一例患者出现不良反应。治疗前后患者血常规、肝肾功能、血钙、血磷均在正常范围内。结论:PEMFs能改善原发性骨质疏松症患者疼痛症状,促进骨形成从而提高骨密度。PEMFs治疗原发性骨质疏松症是安全的。  相似文献   

8.
目的:采用低频脉冲电磁场(pulsed electromagnetic fields,PEMFs)对绝经后骨质疏松症患者进行干预,观察其临床疗效并进行为期1年的疗效观察,以探讨PEMFs对骨质疏松患者的短期和远期疗效。方法:将纳入研究的绝经后骨质疏松患者60例分为对照组和研究组。对照组接受为期12个月的常规骨质疏松治疗,包括钙剂、维生素D和二膦酸盐;研究组接受常规治疗的基础上增加30次(1个月)的PEMFs治疗。所有患者在治疗前和治疗后第1、3、6和12个月接受疗效评估,包括疼痛、功能受限指数。腰椎骨密度检查在治疗前,治疗后3、6和12个月接受检查。结果:纳入患者基线水平无显著性差异(P0.05)。治疗后1、3、6和12个月,研究组患者疼痛和功能受限的水平显著低于对照组;治疗后3个月研究组患者骨密度(bone mass density,BMD)改善明显高于对照组,而治疗后6和12个月两组的BMD没有显著性差异。结论:在常规药物治疗的基础上配合PEMFs治疗可在短期内增加对骨质疏松症患者疼痛和运动功能的改善作用且具有较好的远期疗效;对于腰椎骨密度的影响具有较好的效果,但是远期效果不明显。  相似文献   

9.
目的探讨早期功能锻炼对促进骨质疏松症合并椎体骨折患者骨痛及骨密度的影响。方法选择骨质疏松症伴有单纯性椎体骨折患者61例,随机分为两组,即早期功能锻炼组(观察组)和常规治疗组(对照组)。对照组:采取绝对卧硬板床休息,常规抗骨质疏松药物、饮食治疗。观察组:早期指导患者进行四肢康复锻炼,4~6周后进行腰背部康复锻炼。药物及饮食治疗同对照组。结果观察组4~6周后31例患者腰部疼痛明显缓解,骨量增加,骨密度改善,优良率为79%,无效率6%。对照组17例患者腰部疼痛缓解,骨量增加,骨密度改善,优良率61%,无效率14%。观察组疗效明显优于对照组。结论早期有计划的功能锻炼,对促进钙盐的骨沉积,保持和提高骨量,恢复骨质结构,缓解骨痛症状,加速患者功能恢复,具有明显效果。  相似文献   

10.
目的探讨系统化护理干预对绝经后骨质疏松症患者的临床效果。方法选取2013年5月-2015年1月收治的80例绝经后骨质疏松症患者,根据随机数字表法分为对照组和干预组各40例。对照组患者给予常规治疗及护理,干预组患者在常规治疗基础上给予系统化护理干预。6个月后比较2组患者的骨密度值(BMD)、血清骨钙素(BGP)以及生存质量。结果 6个月后,2组腰椎BMD均较干预前有所改善;且干预组腰椎BMD高于对照组。2组BGP较干预前均有所降低,干预组BGP水平明显低于对照组。2组生存质量各条目均较治疗前有明显改善,且干预组患者精神状态、社交活动、健康观念评分改善程度均好于对照组。结论系统化护理干预能够提高绝经后骨质疏松症患者的BMD,降低BGP水平,改善患者的临床症状,提高患者的生存质量。  相似文献   

11.
目的:探讨电磁疗即脉冲磁刺激及中频脉冲电疗治疗在创伤性骨折康复中的临床效果.方法:选择创伤性骨折患者100例,随机分成对照组及试验组各50例.对照组采用常规治疗方法,试验组在常规治疗方法基础上增加脉冲磁刺激及中频脉冲电疗治疗.结果:试验组能迅速的消除肢体肿胀,减轻患肢疼痛,有效地促进骨折愈合.结论:脉冲磁刺激及中频脉冲电疗疗效明显,且无副作用,适用于创伤性骨折.  相似文献   

12.
BACKGROUND: Bone manifestations are a source of disability among patients with Gaucher disease (GD) and a focus of disease management. The effect of enzyme replacement therapy (ERT) on GD bone disease can be limited and may take up to 8 years to become manifest. Miglustat, a glucosylceramide synthase inhibitor, may have a positive influence on GD bone disease. OBJECTIVES: The aim of this analysis was to evaluate the effects of miglustat on bone manifestations and bone mineral density (BMD) in patients with type 1 GD. METHODS: This was a pooled analysis of data collected prospectively over an observation period of 2 years from patients who participated in 3 multinational, open-label clinical trials evaluating the efficacy and tolerability of miglustat 100 mg TID (the currently approved therapeutic dose). Bone manifestations were assessed qualitatively and in relation to treatment and spleen status. The effects of miglustat on BMD were assessed by dual-energy x-ray absorptiometry at the lumbar spine and/or femoral neck. Bone response was defined as a positive change in BMD, based on the change in BMD Z-score from baseline to months 6, 12, and 24. Changes in BMD were also analyzed according to spleen status and baseline severity of osteopenia. RESULTS: The analysis involved 72 patients, including 41 (57%) who had received previous ERT and 20 (28%) who had undergone splenectomy. Patients' mean (SD) age was 41.2 (13.1) years. The most frequent bone-related manifestations at study entry were osteoporosis (43/63 [68%] patients) and bone pain (41/65 [63%] patients). At 2 years, 54/65 (83%) patients reported no bone pain. The reductions in bone pain were comparable among all subgroups, including high-risk patients (ie, splenectomized). No new cases of bone crisis, avascular necrosis, or pathologic fractures were reported. BMD Z-scores were improved from baseline at both the lumbar spine and femoral neck at each time point (months 6, 12, and 24) (P < 0.001). As early as 6 months after the initiation of miglustat monotherapy, significant increases from baseline in the BMD Z-score were observed at both the lumbar spine (mean, 0.15; P = 0.022) and femoral neck (0.23; P < 0.001); the increases remained significant at 12 months (0.19 [P = 0.012] and 0.21 [P = 0.017], respectively) and 24 months (0.21 [P = 0.015] and 0.18 [P = 0.039]). Significant increases in BMD Z-scores were observed at the femoral neck in splenectomized patients (P < 0.001) and at both sites in osteoporotic patients (lumbar spine: P < 0.001; femoral neck: P = 0.006). CONCLUSION: This pooled analysis of 3 open-label studies of miglustat 100 mg TID suggests that miglustat monotherapy may reduce the incidence of bone pain and improve BMD in patients with type 1 GD, including those with a history of splenectomy and/or osteoporosis.  相似文献   

13.
潘惠娟 《全科护理》2013,(30):2789-2790
[目的]观察密固达(唑来膦酸注射液)联合护理干预对老年骨质疏松症病人骨痛及骨密度(BMD)的疗效.[方法]将90例老年骨质疏松症病人随机分为观察组和对照组各45例,对照组给予口服钙剂及维生素D,观察组在此基础上加用密固达联合护理干预综合治疗.比较两组治疗前后骨痛程度及BMD变化.[结果]观察组治疗后骨痛症状缓解,与对照组总有效率比较差异有统计学意义(P〈0.05);观察组治疗后骨密度增加,与对照组比较差异有统计学意义(P〈0.05).[结论]密固达联合护理干预能有效提高老年骨质疏松症病人的BMD,改善骨痛症状.同时,通过护理干预能使病人积极配合治疗和护理.  相似文献   

14.
《Annals of medicine》2013,45(3):230-235
Background. Teriparatide is a potent anabolic agent for severe osteoporosis.

Objectives. A primary objective of this retrospective study was to define the efficacy of teriparatide in terms of bone mineral density (BMD) changes and relief of back pain in clinical practice.

Methods. The patient population comprises 119 osteoporotic patients treated with teriparatide for median 539 (range 179–926) days.

Results. The mean BMD gain was 0.9% in the total hip (P = 0.0075), 2.1% in the femoral neck (P = 0.0006), and 8.5% in the lumbar spine (P = 0.0085). In the whole patient population age associated inversely with BMD changes in the total hip (P = 0.019) and in the femoral neck (P = 0.0036). A history of significant bisphosphonate pretreatment (n = 90) reduced BMD response in the total hip (P = 0.039). The total exposure of any prior bisphosphonate was negatively correlated with BMD response in the total hip (P = 0.0421). Half of the patients reported relief of back pain during the treatment. Leg pain, nausea, and dizziness were most frequent adverse concerns.

Conclusions. Teriparatide works in clinical practice as well as in clinical trials. Younger subjects benefited more than older patients from teriparatide in the total hip and in the femoral neck. Bisphosphonate pretreatment attenuated teriparatide-induced BMD gain.  相似文献   

15.
李浩  李晓淼  沈奕  王伟力 《医学临床研究》2020,37(4):539-541,544
[目的]探讨骨密度水平对老年脊柱骨折患者骨痛和手术预后的影响.[方法]收集2017年7~12月在本院骨科接受手术治疗的老年(>60岁)脊柱骨折患者,采用双能X线测定骨密度,根据骨密度水平分为低水平骨密度组(T值<1.0)和高水平骨密度组(T值≥-1.0).两组均采用模拟疼痛评估量表(VAS)评估疼痛程度,随访记录患者的术后相关指标评估其预后状况.[结果]低水平骨密度组在术后12 h、24 h VAS量表评分均显著高于高水平骨密度组(P<0.05),而术后48 h两组VAS量表评分比较差异无统计学意义(P>0.05);两组术后至出院的天数、总住院天数、术后并发感染及低钾血症构成比比较差异有统计学意义(P<0.05);术后12 h VAS评分与患者骨密度水平呈显著负相关(P<0.05),而术后24 h、48 h VAS评分与患者骨密度水平无显著相关性(P>0.05).骨密度水平减低是术后骨痛程度增加的危险因素(P<0.05);此外,术后并发感染、骨折段数和椎体压缩程度也均为骨痛程度增高的危险因素(P<0.05).[结论]低骨密度水平可能是影响老年脊柱骨折患者骨痛水平的一个危险因素,同时低骨密度水平也可影响患者术后的预后状况.  相似文献   

16.
物理治疗缓解老年性骨质疏松症疼痛的疗效观察   总被引:2,自引:0,他引:2  
目的观察物理治疗在缓解老年骨质疏松症疼痛及提高生存质量中的疗效.方法39例具有自发性疼痛的老年原发性骨质疏松症患者随机分为两组Ⅰ钙剂对照组单纯服用钙剂;Ⅱ钙剂加理疗组钙剂辅以超声波及间动电治疗.以疼痛程度、生存质量及骨密度值为观察指标,分别比较两组在治疗前及治疗20d后各项指标的变化.结果钙剂加理疗组患者在治疗20d后疼痛程度明显减轻,生存质量明显提高,骨密度与治疗前相比无明显差异.结论药物配合物理治疗在缓解老年原发性骨质疏松症疼痛及提高生存质量方面比单纯药物治疗具有更好疗效.  相似文献   

17.
Introduction: The identification of therapeutic strategies aimed both at preventing and treating osteoporosis and osteoporotic fractures has become increasingly important; in particular, it is essential to promote adequate patient adherence to treatment. The primary aim of this study was to evaluate the effects on lumbar and femoral bone mass density (BMD) after two different intramuscular (IM) dosing regimens of clodronate (CLD), a bisphosphonate shown to be efficacious in reducing the incidence of both vertebral and nonvertebral fractures. Secondary aims were the assessments of bone resorption markers, safety, tolerability, pain, and patient compliance. Methods: Sixty women with postmenopausal osteoporosis were randomized to two groups: group A (CLD 100 mg IM weekly for 12 months), and group B (CLD 200 mg IM every 2 weeks for 12 months). All patients received 1 g of calcium supplemented with 800 IU vitamin D3, orally, once daily for 12 months Lumbar and femoral BMD, measured by DEXA Norland XR-36 (Norland Co., Fort Atkinson, WI), and bone turnover markers were assessed at baseline and at 12 months. Each patient was administered a visual analog scale of pain at baseline and after 6 and 12 months of treatment. Results: A significant increase of BMD in both groups and in both skeletal sites was observed at 12 months versus baseline. In group A (n=28), lumbar BMD increased by 3.5% and femoral BMD by 2.1%; in group B (n=32), lumbar and femoral BMD rose by 3.4% and 2.2%, respectively. No difference was observed between groups. Bone resorption markers significantly reduced from baseline. Pain significantly improved as early as after 6 months of therapy and even more after 12 months, although no significant difference between the two groups was observed. The most common side effect was pain at the injection site, particularly in group B. Six patients in group A discontinued treatment and failed adherence to the therapeutic protocol. Conversely, no patient from group B discontinued therapy. Conclusion: In agreement with published data, in our two groups of patients, therapy with IM CLD at the doses of 100 mg/week and 200 mg/2 weeks was shown to be effective in increasing BMD, without differences between the two dosing regimens in all assessed efficacy parameters. Therefore, the “twice-a-month” regimen with 200 mg IM CLD may well promote an improved adherence with the same clinical efficacy and safety profile.  相似文献   

18.
【目的】观察唑来磷酸治疗老年骨质疏松症的缓解疼痛的效果及安全性。【方法】应用唑来磷酸注射液治疗18例65-85岁老年骨质疏松症患者,观察治疗前后患者骨痛的缓解情况,血钙、磷、碱性磷酸酶变化及不良反应情况,采用双能x线骨密度仪测定患者治疗前后骨密度变化。【结果】治疗后患者骨痛症状明显改善,血钙、磷无显著变化(P〉0.05),血碱性磷酸酶明显下降(P〈0.05),骨密度较治疗前显著增加(P〈0.01,P〈0.05),18例患者不良反应发生率为56.0%,但患者能耐受。【结论】唑来磷酸是治疗老年性骨质疏松症的安全有效性药物。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号